

**CLINICAL ADVANCES SPOTLIGHT**  
**CME Lunch Symposium**

**Advances in LDL Lowering:**  
**A Focus on PCSK9 Inhibitors' Journey from Genetics to Clinical Practice**  
Friday, October 23, 2015 • Sheraton Boston Hotel  
11:45 – 1:45pm  
*Supported by an educational grant from Amgen, Inc.*

**SYMPOSIUM OVERVIEW**

One of the more remarkable scientific advances of this century is the discovery of PCSK9, which the body uses to regulate LDL-C. In little more than a decade, the first PCSK9 inhibitors have received FDA approval. This Clinical Advances will highlight key events that allowed for rapid development of the drug from bench to bedside. It will also discuss the relationship between atherosclerosis progression and LDL-C levels and provide expert interpretation of clinical guidelines on lipid management and clinical trial results. An interactive panel discussion will explore how PCSK9 inhibitors can be integrated into the management of patients with severe lipid disorders to help achieve lipid management goals, reduce cardiovascular risk, improve outcomes for patients, and potentially in the future, even be used as primary prevention.

**LEARNING OBJECTIVES**

Upon completion of these educational activities, participants will be better able to:

- Describe the importance of lowering LDL-C levels in high-risk patients, including those with residual ASCVD risk such as patients with FH, and/or those with statin intolerance.
- Assess the genetic basis and mechanistic rationale for lowering LDL-C through novel pathways, the importance of LDL receptor recycling in cholesterol homeostasis, and through the use of monoclonal antibodies.
- Review the latest clinical trial data for the novel LDL-C lowering agents, PCSK9 inhibitors, and their potential application to address ASCVD risk in clinical practice.
- Review the physiologic rationale for the new drug classes, practicalities of their administration; including potential for use as replacement or complementary treatment for patients on a statin; patient selection for use of these drugs; as well as the need for additional outcomes studies.

**AGENDA & FACULTY**

**Welcome and Introductions**

Chairperson: **Marc S. Sabatine, MD**

**A Natural Human Experiment: PCSK9 and Cholesterol**

Presenter: **James A. Underberg, MD**

**Safety and Tolerability of Monoclonal Antibodies Targeted Against PCSK9**

Presenter: **Michael J. Koren, MD**

**PCSK9 Inhibitors: Clinical Evidence for a New Therapeutic Approach to LDL-C Lowering**

Presenter: **Marc S. Sabatine, MD**

**Expert Panel Discussion: Practicalities of PCSK9 Inhibitors:  
Promises, Pitfalls and Unanswered Questions**

Moderator: **Marc Sabatine, MD**

Discussants: **Seth J. Baum, MD, Michael Koren, MD, James A. Underberg, MD**

**Questions and Answers, Summary, Closing Remarks**

Chairperson: **Marc Sabatine, MD**

Discussants: **All faculty**

*Note: Agenda and Faculty subject to change.*